With increased biomarker and specialty lab data being incorporated into FDA submissions, drug developers are running into challenges as they prepare data that comply with new regulatory requirements. Precision for Medicine’s Jared Kohler, Angela Quigley, and Tobias Guennel identify the obstacles and solutions to overcome them.
To read the full article, please click here.